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Abstract 
Objective: 
The objective of this selective EBM review is to determine whether or not starting antiretroviral 
therapy (ART) in HIV positive adults with CD4 cell count of <300 cells/µl within four weeks of 
initiating new tuberculosis therapy more effective in reducing mortality rates than starting ART 
four weeks or later after initiating new tuberculosis therapy. 
 
Study Design:  
Systematic review of three English language primary studies published in the New England 
Journal of Medicine in 2011. 
 
Data Sources: 
Three open label, randomized, controlled trials published in 2011, comparing the timing of ART 
for HIV+ adults with confirmed or suspected new TB infections to reduce mortality rates in 
reference to initiating TB therapy were obtained using PubMed, Medline and OVID  databases. 
 
Outcome Measured: 
Outcomes measured include mortality rate, new AIDS defining illness, and immune 
reconstitution inflammatory syndrome (IRIS).  
 
Results: 
Karim et. al. (2011) found in patients with a CD4+ cell count less than 300 cells/µl the incidence 
rate of death was 7.0% in the earlier ART group compared to 6.9% in the later ART group, with 
IRIS occurring in 20.0% in the early ART and 8.4% in the late ART group.  In groups with 
CD4+ cell counts of less than 50 cells/µl the mortality rates were 8.1% and 20.0% and incidence 
rates of IRIS as 37.8% and 11.4% for early and late ART respectively. Blanc et. al. (2011) found 
in patients with CD4+ cell counts of 200 or less cells/µl a 17.8% mortality rate in the early ART 
group compared to a 27.4% mortality rate in the late ART group.  They also found a significant 
increase in IRIS in the early ART group, 42.5% compared to just 20.0%. Havlir et. al. (2011) 
found a 7.7% mortality rate in the early ART group and 9.2% in the late ART group with both 
groups starting with a CD4+ count of less than 200 cells/µl. For patients with CD4+ T-cell count 
of less than 50 cells/µl, they found the mortality rate and incidence of new AIDS-defining 
illnesses was significantly lower in the early ART group 15.5% vs. 26.6% in the later group.  
 
Conclusions: 
Karim et al. and Havlir et al. both found that starting ART early in TB therapy showed no 
significant statistical difference in mortality outcomes in patient with a CD4+ cell count less than 
300 cells/µl, but if the group has a CD4+ count of less than 50 cells/µl, new AIDS related illness 
and death were reduced. Blanc et al. found that survival improved when ART was initiated 
within 2 weeks of starting TB therapy in HIV + adults with a CD4+ count of 200 or less cells/µl. 
All three studies showed an increase incidence of IRIS when ART was started within four weeks 
of initiating TB therapy.  
 
Key Words:  
“HIV/AIDS”, “Tuberculosis”,  “TB”, “timing of antiretroviral therapy” 
 
	  	  Erlien;	  ART	  Timing	  in	  TB	  therapy	  1	  	  	  
Introduction 
Tuberculosis (TB) is a contagious infection, mainly bacterial, that is spread via airborne 
particles. It primarily affects the lungs but can spread to different organs in the body. In healthy 
populations, most TB infections can be controlled by the body and remain latent. In populations 
of extreme age or immunocompromise TB is more likely to be active and symptomatic, leading to 
higher mortality rates. A recent report from WHO noted that in 2011 8.7 million people 
worldwide became ill with TB and 1.4 million died.1 In the U.S. in 2011 a total of 10,528 new TB 
cases were reported and, of those, 82.5% had information on their HIV status and 7.7% were HIV 
positive.2  The treatment of TB depends on whether the person has latent or active TB as well as 
specific sensitivities appropriate for the region. For latent infections, the person has been exposed 
to the bacteria but does not have symptoms and cannot spread the disease. Treatment generally 
includes a single drug, Isoniazid, taken daily for 6-9 months which aims at destroying the TB 
bacteria and preventing active TB. Patients with active TB are symptomatic and able to spread the 
disease. Drug therapy is more complicated and longer to prevent multidrug-resistant TB. After an 
intense 8 week induction phase of drug therapy which includes daily Isoniazid, Rifampicin, 
Pyrazinamide and Ethambutol, the continuation phase follows with four months of daily Isoniazid 
and Rifampicin. (treatments vary by country and disease susceptibility)3,4,5 
Acquired Immune Deficiency Syndrome (AIDS) results from the Human 
Immunodeficiency Virus (HIV), which is transmitted through infected body secretions; primarily 
blood, semen, breast milk and vaginal fluid. The CD4+ T-cells are the primary site of infection 
and therefore often used to measure the status of the immune system as well as predict severity of 
HIV infection. HIV/AIDS is the largest cause of death from an infectious agent worldwide. 
Although the number of new infections and AIDS related deaths are declining worldwide, in 2011 
it was estimated that there were 34.2 million people living with HIV, 2.5 million newly infected 
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and 1.7 million deaths.6 In the U.S. there was an estimated 48,100 new HIV cases diagnosed in 
20097 in addition to the 1.2 million HIV positive people already diagnosed in the U.S.8 Of those 
living with HIV worldwide, they accounted for 13% of all new tuberculosis cases and about 
360,000 deaths from HIV-related TB.9  Therapy for HIV/AIDS is based on the CD4+ cell count 
as well as symptoms or co-infections. ART is multidrug and the treatment selected depends on 
viral strains, sensitivities and available medications in the region. It aims to completely suppress 
the viral replication. The treatment of HIV includes combinations of drugs such as: Efavirenz, 
Lamivudine, Tenofovir, Emtricitabine, Stavudine and Didanosine. (treatments vary by country 
and disease susceptibility)3,4,5 
Physician Assistants will inevitably encounter patients with either TB, HIV/AIDS or both, 
and those specializing in infectious disease will be responsible for the treatment plans of such 
patients. It is important for Physician Assistants to understand the indications and complications 
that accompany treating these complex cases.  
In 2006 in the U.S. the mean annual cost of HIV treatment was $19,912, but costs ranged 
from $40,678 in patients with a CD4 cell count of <50 cells/µl to $16,614 in patients with a CD4 
cell count of >500 cells/µl.10  In 2010, the CDC estimated the lifetime cost of HIV treatment to be 
nearly $380,000.11 TB treatment involves multiple medications and lengthy treatment and can 
range from $101, 553 for hospital treatments to $27,490 with less expensive medicines in the 
US.12 Data were unavailable as to the combined cost of HIV positive persons co infected with 
TB. 
Both TB and HIV are serious conditions, but when they are co-infecting a patient it can 
become a lethal combination. The WHO estimates that at least 33% of the 34 million diagnosed 
HIV positive are infected with TB, and that population is up to 34 times more likely to progress 
from latent to active TB than an HIV negative population1. TB continues to be a significant cause 
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of death in HIV positive adults, up to 25% according to the WHO. The current 2009 WHO 
guideline is to start ART as soon as possible after TB therapy is started without regard to the 
patient’s CD4+ T-cell count.13 It has been proposed that starting ART early (within four weeks) 
of TB treatment can be beneficial in reducing mortality rates in HIV positive patients with any 
CD4 cell counts, but more effective in patients with lower CD4 cell counts. 
ART is important in HIV patients with active TB infections but there is concern with 
starting ART during the induction phase which can cause a high pill burden, drug interactions and 
an increased likelihood of immune reconstitution inflammatory syndrome (IRIS) when both 
treatments are combined.3 
Objective  
The objective of this selective EBM review is to determine whether or not starting HIV 
therapy within the first 4 weeks of a positive TB test in adults with a CD4 cell count of <300 
cells/µl has a lower mortality rate than waiting to start treatment until after 4 weeks of TB 
treatment. 
Methods  
All three studies in this review were open-labeled randomized controlled studies, one 
being a prospective study (Table 1). The populations selected include: HIV positive, >13 years 
old, CD4 cell count of <300 cells/µl, suspected or confirmed TB infection, no previous ART or 
TB treatments. The interventions used in the studies were dependent upon disease susceptibility, 
countries involved, medications available and their specific protocol. The ART includes: 
Efavirenz, Lamivudine, Tenofovir, Emtricitabine, Stavudine and Didanosine. TB therapy 
includes: Isoniazid, Rifampin, Ethambutol and Pyrazinamide. Each study looked at the timing of 
starting ART in reference to initiating new TB treatment. The earlier start of ART was within four 
weeks of initiating TB therapy and the later start of ART was four weeks or more after initiating 
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TB therapy. The outcomes measured qualified as patient oriented evidence that matters (POEM) 
and encompassed mortality rates, new AIDS defining illness, and IRIS. The commonality 
between the three studies were mortality rates and IRIS.  
 A detailed search by the author using PubMed, Medline and OVID was conducted using 
the key words “HIV/AIDS”, “TB”, “timing of antiretroviral therapy”. All studies were published 
in English in The New England Journal of Medicine in 2011. Inclusion criteria for the articles 
included: HIV positive, TB suspected or confirmed, negative pregnancy test, no previous ART or 
TB therapies and patients over 13 years old, CD4 cell count <500 cells/µl, randomized controlled 
trials, and mortality measured as an outcome. The exclusion criteria used were: patients under 13 
years old, pregnant or breast feeding, previous ART or TB treatment, CD4 >500 cells/µl, outcome 
not evaluating mortality rate. The summary of statistics reported and/or used include p-values, 
95% confidence intervals (CI), hazard ratio and incidence-rate ratio.  
Outcomes measured  
In the 2011 study by Halvir et al., the primary end point was survival without a new AIDS 
defining illness over the 48 week study. An independent reviewer unaware of group assignments 
used standardized definitions of AIDS defining illness to assess the diagnosis. TB-associated 
IRIS was confirmed by a reviewer unaware of study group assignment. The cause of death was 
reviewed by study members unaware of the study group assignments. Clinical and laboratory 
evaluations were completed upon entry into the study, at weeks 4, 8, 12 and 16 and then every 8 
weeks until the completion of the study at 48 weeks. At conclusion, the Kaplan-Meier method 
was used to calculate proportions of test subjects which survived without a new AIDS event. 
Plasma HIV-1 RNA and CD4+ cell counts were measured at Division of AIDS certified 
laboratories. Participants were taken from Asia, North America, Africa and South America. 
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Table 1- Demographics and Characteristics of studies 
Study Type # of Pts Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions* 
Havlir3 
(2011) 
Open 
Label, RCT 
806 total 
pt from 
Africa, 
Asia, N. 
America 
and S. 
America 
median 
age 34y 
 
Age >13 with 
CD4 count 
<250 
cell/mm3 
being treated 
for TB and 
naive to 
ART, 
negative 
pregnancy 
test 
Age <13, 
previous 
ART, breast-
feeding, 
history of 
resistant TB 
68 (17%) 
did not 
complete 
the early-
ART arm. 
 
62 (15%) 
did not 
complete 
the late-
ART arm. 
ART:  
EFV 600mg qd,  
FTC 200mg qd,  
TDF 300mg qd 
 
TB:  
All patients received R 
or other Rifamycin-
based treatment 
according to WHO and 
country guidelines 
Blanc4 
(2011) 
Prospective
, Open 
Label RCT 
661 total 
pt from 
Cambodia 
median 
age 
35.5y  
 
Age >18 with 
CD4 count 
<200 
cell/mm3 
with a 
positive TB 
spear and 
naive to 
ART, 
negative 
pregnancy 
test 
Age <18, 
negative HIV 
test or 
negative TB 
spear, CD4+ 
>200 
cell/mm3, 
pregnant or 
breast-
feeding, 
impaired 
hepatic 
function, 
previous ART 
73 (22%) 
did not 
complete 
the early-
ART arm. 
 
104 (32%) 
did not 
complete 
the late-
ART arm. 
ART: 
EFV 600mg qd, 
D4T 30 mg/3TC 150 
mg, 1 tablet BID 
 
TB: 
2 months of  
E15-20 mg/kg qd,  
H 4-5 mg/kg qd,  
R10 mg/kg qd,  
Z 20-30 mg/kg qd, 
followed by 4 months of 
H 10 mg/kg qd,  
R 4-5 mg/kg qd 
 
Karim5 
(2011) 
Open 
Label, RCT 
642 total 
pt from 
South 
Africa 
median 
age 34.4 ±	 8.4 y Age >18 with CD4 count <500 
cell/mm3 
with a 
positive TB 
spear and 
naive to 
ART, 
negative 
pregnancy 
test 
Age <18, 
negative HIV 
test or 
negative TB 
spear, CD4+ 
>500 
cell/mm3, 
pregnant or 
breast-
feeding, 
impaired 
hepatic 
function, 
previous ART 
45 
(22.7%) 
did not 
complete 
the early-
ART arm. 
 
26 
(15.9%) 
did not 
complete 
the late-
ART arm. 
ART: 
enteric-coated 
Didanosine (250 mg if 
the pt weight was <60 kg 
and 400 mg if weight 
was ≥60 kg),  
3TC 300 mg qd,  
EFV 600 mg qd 
 
TB: 
2 months of RHZE 
(150,75, 400, 275)mg 
30-37 kg 2 tabs, 38-54kg 
3 tabs, 55-70kg 4 tabs 
five times/week, 
followed by 4 months of 
RH (150, 75)mg 30-37 
kg 2 tabs, 38-54kg 3 
tabs, or RH (300,150)mg 
55-70kg 4 tabs five 
times/week. 
*Drug Abbreviations:   
Antiretroviral  (ART) Medications; EFV-Efavirenz, FTC-Emtricitabine, TDF-Tenofovir 
disoproxil fumarate, D4T-Stavudine, 3TC-Lamivudine 
Tuberculosis (TB) Medications; R-Rifampicin, H-Isoniazid, Z-Pyrazinamide, E-Ethambutol 
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Substitutions for ART drugs were permitted if necessary to manage toxic effects. There were 
no significant demographic differences between study groups.  
Blanc et al. collected data from five Cambodian hospitals from 2006 to 2009. The primary 
end point was survival with secondary end points being IRIS events, CD4+ T-cell count, 
evolution of drug resistant TB, medication side effects and viral load. The CD4+ T-cell count and 
plasma HIV RNA viral load were measured at weeks 8, 26, 50 and 78 and then every 6 months. 
Participants were followed for 50 weeks after the enrollment of the last patient. Comparisons 
between subject groups were performed using Student’s t-test for continuous variables and chi-
square test of the Fisher’s exact test for categorical variables. Participant survival was analyzed 
using Kaplan-Meier estimates with the log-rank test comparing between groups. There were no 
significant differences between the study groups in regards to their baseline demographics.  
In the 2011 South African study by Karim et al, the primary outcome was incidence rate of 
AIDS or death. IRIS was measured as a secondary outcome. Outcomes were analyzed using the 
Kaplan-Meier curves. Poisson approximations were used to calculate confidence intervals for the 
incidence-rate ratios. For confounding variables, Cox proportional-hazards regression was used 
while the Fisher’s exact test was used for analyzing categorical data. For continuous data, 
unpaired t-tests or the Wilcoxon two-sample test was used. At baseline the two sample groups 
had similar demographics. Duration of the study lasted 18 months after randomization or at the 
time of death or AIDS-defining illness or withdrawal from the study, whichever occurred first.  
Results 
Halvir et al. (2011) found that there was no statistical difference between the early ART and 
later ART groups in the mortality rate or new AIDS-defining illness when the patients had a 
CD4+ T-cell count of 250 cells/µl or less. In the early ART group they had 26 new AIDS-
defining illnesses and 31 (8%) deaths compared to 37 new AIDS-defining illnesses and 37 (9%) 
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deaths in the later ART group (95% CI, -1.8 to 8.1; P= 0.45) when stratified according to the 
CD4+ cell count (Table 2). As calculated from the mortality rates the number needed to treat to 
prevent mortality is 64 patients. Of the deaths during the study, 68% and 57% were attributed to 
HIV-related disease in the early and late ART groups respectively.  When a subgroup analysis 
was done for patients with CD4+ T-cell count of less than 50 cells/µl, they found the mortality 
rate and incidence of new AIDS-defining illnesses was significantly lower in the early ART 
group 15.5% vs. 26.6% (95% CI, 1.5 to 20.5; P=0.02). Medication adverse reactions occurred in 
18% of the total sample population with similar numbers between groups (Table 3). Twenty-one 
of the 783 participants, 14 in the early arm and 7 in the later arm, switched ART therapies due to 
adverse reactions. A total of 56% of patients completed TB treatment without modification or 
interruption without significant difference between arms.  
The CAMELIA study by Blanc et al. (2011) found in patients with CD4+ T-cell counts of 
200 or less cells/µl a mortality rate in the early ART group was 8.28 per 100 person-years, or 
17.8%, (95% CI, 6.42 to 10.69) and 13.77 per 100 person-years, or 27.4%, for the late ART group 
(95% CI, 11.20 to 16.93) (P=0.002); see Table 2. According to these data the number needed to 
treat to prevent a mortality is 11. When Blanc et al. looked at patients with a CD4+ T-cell count 
of less than 50 cells/µl, they found the hazard ratio did not significantly differ between the early 
and late ART treatment groups (P=0.49). They also found a significant increase in IRIS in the 
early ART group, 42.5% compared to just 20.0% in the later group. The incidence within the first 
50 weeks of the study was 3.76 cases per 100 person-months (95% CI, 3.14 to 4.47) with the 
early ART group, and 1.53 cases per 100 person-months in the later ART group (95% CI, 1.13 to 
2.03) (P < 0.001). Of the 332 participant in the early ART group, 259 (78.0%) completed the 
study, and 225 (68.4%) of the 329 participants in the late ART group completed the study. Drug 
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toxicity was the second most common cause of death following TB. In the early ART group, 
there were 2.93 per 100 person-month serious drug-related adverse effects noted (95% CI, 2.85 to 
3.32) and 3.21 events in the later ART group (95% CI, 2.83 to 3.63; P=0.31); see Table 3. 
Table 2. Mortality rates according to study for early vs. late ART. 
Study Author Deaths as % in Early ART group 
Deaths as % in 
Later ART group Statistical Values 
Havlir et al. 7.7 9.2 95% CI, -1.8 to 8.1; P= 0.45* 
Blanc et al. 17.8 27.4 Adjusted hazard ratio, 0.62; 95% CI, 0.44 to 0.86; P=0.006 
Karim et al. 7 6.9 Incidence-rate ratio 0.96, 95% CI, 0.44-2.10; P=0.91 
* Statistical values only given in study for combination of "AIDS or Death" 
 
In the final study by Karim et al (2011), they found in patients with a CD4+ T-cell count 
less than 300 cells/µl the incidence rate death was 5.7 cases per 100 person-years, or 7.0%, in the 
earlier ART group compared to 6.0 cases per 100 person-years, or 6.9%, in the later ART group 
(incidence-rate ratio 0.96; 95% CI, 0.44 to 2.10; P=0.91); see Table 2. Although both study arms 
had 15 deaths, since the early group started with one less person the number needed to treat to 
prevent mortality calculated is -76, implying that mortality was higher in the early treated group. 
When the study analyzed death according to the CD4+ T-cell count they found in patients with a 
CD4+ T-cell count of less than 50 cells/µl the incidence rate was 6.3 cases per 100 person-years 
(95% CI, 1.3 to 18.5) in the early ART group, compared to 16.3 per 100 person-years (95% CI, 
6.5 to 33.5) in the later ART group (incidence rate ratio, 0.39; 95% CI, 0.06 to 1.70; P=0.17). In 
groups with CD4+ T-cell counts of less than 50 cells/µl the incidence rate of IRIS was 4.7 times 
higher in the early ART group (P=0.01). In groups with CD4+ T-cell counts of more than 50 
cells/µl the incidence rate of IRIS was only 2.2 times higher in the early ART group (P=0.02).  
Karmin et al noted that 8.9% of early ART participants and 8.8% of the later ART participants 
defaulted on their TB therapy. Ten patients in the early ART and one in the later ART group had 
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to switch ART due to adverse reactions (P=0.006); see Table 3. Change in ART due to virologic 
failure occurred in 6 patients in the early ART and 9 in the later ART (P=0.18). 
Table 3. Adverse events due to treatment regime for early vs. late ART.  
Study Author Percent of patients experiencing adverse 
events to treatment in early ART 
Percent of patients experiencing adverse events 
to treatment in later ART 
Havlir et al. 1.2 0.9 
Blanc et al.* 27 28 
Karim et al. 4.7 0.5 
*Only 21 of the 783 patients (14 in early ART and 7 in later ATR) required a switch in treatments. 
 
Discussion 
 Two of the three studies addressed in this review demonstrate that there is no statistical 
significance in reducing mortality when starting ART in HIV+ adults with CD4+ T-cell counts of 
less than 300 cells/µl within four weeks of initiating new TB treatment.3,5 All of the studies found 
that starting ART earlier resulted in a higher incidence of IRIS.3,4,5 When the studies analyzed 
participants by their CD4+ T-cell count, they all found a significant improvement in the AIDS-
free survival when ART was started early in patients with a CD4+ cell count of less than 50 
cells/µl, despite the increased risk of IRIS. This is perhaps why the CAMELIA study by Blanc et 
al. found a notable improvement in survival; the median CD4+ cell count of their participants was 
25 cells/µl. The CAMELIA study also followed the patients for a longer duration (median follow 
up of 25 months), had a lower overall average of body mass index than the other two studies and 
only enrolled patients with a confirmed TB diagnosis.4   
One limitation in comparing data was in the Havlir et al. study, the 95% CI and P Values 
were calculated for the combination of AIDS-defining illness and death rather than separating 
each into its own statistical finding. The number of deaths also was inconsistently mentioned in 
the report; once claiming only 53 deaths and elsewhere in the paper 68 deaths.3 This study started 
with only 46% of patients having a confirmed TB infection, the remaining were clinically 
suspected.  
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A general limitation of comparing these three studies is that they were conducted in 
different countries and each study with significant drop out rates. The research groups had 
different evaluators to diagnose IRIS and in some cases TB infection. Each country also has its 
own availability of medication, recommendations on its use and guidelines as to when to switch if 
adverse reactions occur. There are also different susceptibilities to both TB and HIV from country 
to country. None of the studies used the exact same medication regimes. The only similarities 
were Efavirenz in ART as suggested by the WHO due to its lower incidence of interaction with 
Rifampicin compared to other ART medications and the combination of TB treatment (Table 1). 
Conclusion 
Although the studies differ in their recommendations for patients with higher CD4+ T-cell 
counts, they all agree that starting ART early in the TB treatment depends more on the immune 
status of the patient than the presence of co-infection between TB and HIV. With CD4+ T-cell 
counts of less that 50 cells/µl, survival is greatly improved despite the increased risk of IRIS and 
high pill burden when ART is started within 4 weeks of the TB therapy. Although the studies 
were large and generally lengthy, it would be ideal to use the same medication regime to ensure 
that adverse reactions or IRIS are a result of the medications only. Further evaluation could also 
be completed using the CD4+ cell count as the dividing factor when all participants start ART 
early in their TB therapy. The current WHO guideline in the US is to begin ART as soon as 
possible after TB therapy is started regardless of the patient’s CD4+ T-cell count but analysis of 
these studies indicate that the 2009 guideline may need revision. The most recent Programmatic 
Update from June 2012 has indicated investigational studies are underway to determine the best 
recommendations.14 Further study is warranted to evaluate a more specific guideline for starting 
ART in regards to the timing of TB treatment and most beneficial CD4+ T-cell count or even 
viral load counts at which ART should be initiated.  
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